Patents Assigned to Adaptimmune Limited
-
Patent number: 11929151Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.Type: GrantFiled: January 26, 2021Date of Patent: March 12, 2024Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
-
Patent number: 11753456Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.Type: GrantFiled: October 14, 2021Date of Patent: September 12, 2023Assignee: Adaptimmune LimitedInventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
-
Patent number: 11725040Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.Type: GrantFiled: October 14, 2021Date of Patent: August 15, 2023Assignee: Adaptimmune LimitedInventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
-
Patent number: 11572400Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.Type: GrantFiled: August 17, 2022Date of Patent: February 7, 2023Assignee: Adaptimmune LimitedInventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
-
Patent number: 11286289Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.Type: GrantFiled: October 8, 2018Date of Patent: March 29, 2022Assignee: ADAPTIMMUNE LIMITEDInventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
-
Patent number: 11203627Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.Type: GrantFiled: April 5, 2017Date of Patent: December 21, 2021Assignee: ADAPTIMMUNE LIMITEDInventors: Conor Hayes, Arsen Volkov, Andrew Gerry, Ellen Border, Edward Carter
-
Patent number: 11124556Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.Type: GrantFiled: September 15, 2016Date of Patent: September 21, 2021Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
-
Patent number: 11084862Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted FMNKFIYEI (158-166) peptide epitope derived from ? Fetoprotein (AFP). Certain preferred TCRs of the invention demonstrate excellent binding characteristics and specificity profiles for this AFP epitope. T cell receptors of the invention may comprise at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain, the alpha chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 2, and/or the beta chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 3.Type: GrantFiled: May 20, 2019Date of Patent: August 10, 2021Assignee: ADAPTIMMUNE LIMITEDInventors: Peter Molloy, Nicholas Pumphrey
-
Patent number: 11017882Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.Type: GrantFiled: June 17, 2015Date of Patent: May 25, 2021Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
-
Patent number: 10937524Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.Type: GrantFiled: June 17, 2015Date of Patent: March 2, 2021Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
-
Patent number: 10689620Abstract: This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment.Type: GrantFiled: April 9, 2018Date of Patent: June 23, 2020Assignee: ADAPTIMMUNE LIMITEDInventors: Bruno Laugel, Kathrin Skibbe
-
Patent number: 10344074Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted FMNKFIYEI (158-166) peptide epitope derived from ? Fetoprotein (AFP). Certain preferred TCRs of the invention demonstrate excellent binding characteristics and specificity profiles for this AFP epitope. T cell receptors of the invention may comprise at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain, the alpha chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 2, and/or the beta chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 3.Type: GrantFiled: January 26, 2016Date of Patent: July 9, 2019Assignee: ADAPTIMMUNE LIMITEDInventors: Peter Molloy, Nicholas Pumphrey
-
Publication number: 20180346904Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV38 gene product and the beta chain variable domain comprises a TRBV2 gene product.Type: ApplicationFiled: September 15, 2016Publication date: December 6, 2018Applicants: IMMUNOCORE LIMITED, ADAPTIMMUNE LIMITEDInventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
-
Patent number: 9976121Abstract: This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment.Type: GrantFiled: September 22, 2017Date of Patent: May 22, 2018Assignee: Adaptimmune LimitedInventors: Bruno Laugel, Kathrin Skibbe
-
Patent number: 9932597Abstract: The present invention relates to a vector system involving replacement of a Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (WPRE) sequence with an unrelated short spacer sequence for efficient expression of nucleotides of interest in a retroviral vector system and methods of delivering and expressing nucleotides of interest to target cells.Type: GrantFiled: October 24, 2014Date of Patent: April 3, 2018Assignee: ADAPTIMMUNE LIMITEDInventor: On Kan
-
Patent number: 9822163Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: October 12, 2016Date of Patent: November 21, 2017Assignee: ADAPTIMMUNE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Patent number: 9512197Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: December 14, 2015Date of Patent: December 6, 2016Assignee: ADAPTIMMUNE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Patent number: 9447410Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.Type: GrantFiled: April 10, 2014Date of Patent: September 20, 2016Assignees: ADAPTIMMUNE LIMITED, IMMUNOCORE LIMITEDInventors: Bent Karsten Jakobsen, Peter Eamon Molloy, Yi Li, Jonathan Michael Boulter
-
Patent number: 9279122Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.Type: GrantFiled: April 9, 2014Date of Patent: March 8, 2016Assignees: ADAPTIMMUNE LIMITED, IMMUNOCORE LIMITEDInventors: Bent Karsten Jakobsen, Peter Eamon Molloy, Yi Li
-
Patent number: 9255135Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.Type: GrantFiled: January 3, 2013Date of Patent: February 9, 2016Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy